Invion Ltd (ASX: IVX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Invion Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $32.12 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 6.42 billion
Earnings per share 0.000
Dividend per share N/A
Year To Date Return N/A
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Invion Ltd (ASX: IVX)
    Latest News

    asx share price increase represented by golden dollar sign rocketing out from white domes of lithium
    Healthcare Shares

    Invion share price (ASX:IVX) rockets 123% on pilot study results

    The company's shares are rocketing to a multi-year high today.

    Read more »

    a woman
    Share Gainers

    Why the Invion share price rocketed 225% higher today

    The Invion Ltd (ASX:IVX) share price is rocketing higher on Wednesday. Here's why...

    Read more »

    a woman
    Share Gainers

    Why the Invion share price zoomed 86% higher today

    The Invion Ltd (ASX:IVX) share price almost doubled in value this morning after releasing an update on IVX-P02...

    Read more »

    a woman
    ⏸️ Investing

    Here's why Invion Ltd stock plunged 24.4% today

    Invion Ltd (ASX:IVX) is a small-cap drug developer which has lost 62% of its value since August

    Read more »

    IVX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Invion Ltd

    Invion Ltd is an Australian clinical-stage pharmaceutical drug development company. It is engaged in the development of PhotoDynamic Therapy (PDT) for cancer treatments. The company produces topical and intravenous products suitable for use in skin cancer and solid tumors, such as ovarian, prostate, and lung cancer.

    IVX Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    24 May 2024 $0.01 $0.00 0.00% 11,339,156 $0.01 $0.01 $0.01
    23 May 2024 $0.01 $0.00 0.00% 272,161 $0.01 $0.01 $0.01
    22 May 2024 $0.01 $0.00 0.00% 3,054,246 $0.01 $0.01 $0.01
    21 May 2024 $0.01 $0.00 0.00% 205,664 $0.01 $0.01 $0.01
    20 May 2024 $0.01 $0.00 0.00% 617,309 $0.01 $0.01 $0.01
    16 May 2024 $0.01 $0.00 0.00% 300,000 $0.01 $0.01 $0.01
    14 May 2024 $0.01 $0.00 0.00% 820,583 $0.01 $0.01 $0.01
    13 May 2024 $0.01 $0.00 0.00% 850,128 $0.01 $0.01 $0.01
    10 May 2024 $0.01 $0.00 0.00% 150,015 $0.01 $0.01 $0.01
    09 May 2024 $0.01 $0.00 0.00% 2,754,015 $0.01 $0.01 $0.01
    08 May 2024 $0.01 $0.00 0.00% 8,872,394 $0.01 $0.01 $0.00
    07 May 2024 $0.01 $0.00 0.00% 107,127 $0.01 $0.01 $0.01
    06 May 2024 $0.01 $0.00 0.00% 1,811,339 $0.01 $0.01 $0.01
    03 May 2024 $0.01 $0.00 0.00% 3,056,860 $0.01 $0.01 $0.01
    02 May 2024 $0.01 $0.00 0.00% 293 $0.01 $0.01 $0.01
    30 Apr 2024 $0.01 $0.00 0.00% 725,000 $0.01 $0.01 $0.01

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    18 Jan 2024 Robert (Rob) Merriel Exercise 2,900,000 $13,050
    Exercise of options.
    18 Jan 2024 Robert (Rob) Merriel Buy 2,900,000 $13,050
    Exercise of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Chiat Thian Chew Chief Executive OfficerExecutive ChairmanExecutive Director Dec 2017
    Mr Chew has over 25 years of experience in investing, finance and transforming business operations. He is Managing Partner at Polar Ventures, a private investment and consulting firm that provides capital, strategic and operating solutions, focusing on small to mid-sized enterprises in Asia. Mr Chew was previously an Executive Director at Goldman Sachs (Hong Kong and New York) responsible for the firm's proprietary investments including growth capital, private equity and special situations in both private and public companies. Prior to this, he was a Consultant Project Manager to Morgan Stanley, New York. Mr Chew also held a number of positions in KPMG across Asia Pacific including Director at KPMG Consulting (Singapore and Sydney) where he led several large scale operational restructuring, post-merger integration, transformation, and business performance improvement programs. As a Senior Manager at KPMG (Taipei and Melbourne), he performed financial and information technology audit, risk and assurance engagements across multiple industries. Mr Chew is an Adjunct Professor at HKUST's MBA program.
    Mr Alan Yamashita Non-Executive Director Feb 2019
    Mr Yamashita is a corporate consultant and investment professional, with over 40 years' experience in investment management, investment banking and alternative investment throughout the APAC region. From 1999 to 2005, Mr Yamashita was President and CEO of Search Investment Group and founding CEO and CIO of Search Alternative Investment Ltd (SAIL), a major private global hedge fund and private equity investment practice headquartered in Asia. Prior to Search Investments Group, Mr Yamashita was Managing Director and Head of Asia Capital Markets for Merrill Lynch from 1996 to 1998. Mr Yamashita is currently Managing Partner at Polar Ventures and has held positions as a 16-year veteran of Goldman Sachs and an advisor to various companies, including Plantation Timber Partners, Wuhan; Duty Free Shoppers, Asia; TVSN, Shanghai; and Mizuho Alternative Investments LLC.
    Mr Robert (Rob) Merriel Non-Executive Director Aug 2020
    Mr Merriel is has over 35 years of experience working in medical research (Hudson Institute of Medical Research and Baker Institute), public healthcare services (Melbourne Health and Southern Health) and commercial organisations (Pacific Dunlop and Deloitte Consulting). He has been a Director of two Venture Capital Funds and a Director and Company Secretary of several biotechnology focused medical research institute spin-off companies. Mr Merriel was appointed as the Chief Financial Officer, Chief Commercialisation Officer and Company Secretary of the Hudson Institute of Medical Research in May 2014, positions he continues to hold today. He is member of Risk Committee.
    Mr Alistair Bennallack Non-Executive Director Oct 2020
    Mr Bennallack is currently the Group Chief Financial Officer of Village Roadshow Pty Ltd, Head of Risk for Village Roadshow Pty Ltd and Chief Executive Officer of Village Roadshow Theme Parks Asia, a division of Village Roadshow Theme Parks Pty Ltd. He is the primary executive responsible for conceptualising, executing and delivering Village Roadshow's expansion into China and Asia. He is a former member of the Village Roadshow Ltd Executive Committee, current member of the Village Roadshow Theme Parks Executive Committee and current member of all Village Roadshow Pty Ltd's Management and Risk Committees. His previous roles have included Chief Financial Officer of Village Roadshow Ltd and General Manager Business Affairs of Village Roadshow Corporation Pty Ltd (controlling shareholder of Village Roadshow Ltd.). He is chair of risk committee.
    Ms Claire Newstead-Sinclair Company Secretary Nov 2021
    -
    Claire Newstead-Sinclair Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Polar Ventures Limited 545,217,721 8.49%
    BNP Paribas Nominees Pty Ltd <IB Au Noms Retail Client Drp> 537,894,371 8.38%
    Rmw Cho Health Technology Limited 321,428,571 5.01%
    Rmwc Pty Ltd <Rmwc Family A/C> 314,547,156 4.90%
    Mr Honsue Cho 284,626,482 4.43%
    Ngpdt Greater China Limited 272,652,297 4.25%
    Mei Jun Lin 272,500,000 4.24%
    Acslnc Pty Ltd <Acslnc Family A/C> 229,950,000 3.58%
    Citicorp Nominees Pty Limited 162,657,602 2.53%
    Shengli Wang 136,288,074 2.12%
    Yong Chen 110,000,000 1.71%
    Ms Dandan Wang 104,719,526 1.63%
    Surfit Capital Pty Ltd 100,000,000 1.56%
    Mr Yong Chen 93,253,079 1.45%
    Mr Shengwei Ou 77,304,171 1.20%
    Shubo Miao 73,333,333 1.14%
    Mr Esmond Wong & Mrs Quynh Thi Kim Nguyen 67,564,765 1.05%
    Eq Investment Pty Ltd 62,500,000 0.97%
    Ms Yinghua Ma 61,000,000 0.95%
    Hsbc Custody Nominees (Australia) Limited 51,463,958 0.80%

    Profile

    since

    Note